Aminoacids and derivatives

<p>Applications Minor Cisapride (C496400) metabolite.<br>References Meuldermans, W., et al.; Drug Metab. Disposition, 16, 410 (1988), Lowry J., et al.; Clin. pharmacol. ther., 73, 209 (2003), Shao L., et al.: Bioorg. Med. Chem. Lett., 19, 5679 (2009),<br></p>

<p>Applications 5-Aminolevulinic Acid Hydrochloride (cas# CAS:5451-09-2) is a useful research chemical.<br></p>

<p>Applications Labelled N2-Lauroyl-L-glutamine (L178650). N2-Lauroyl-L-glutamine is used as a solubilizing detergent in a novel protein refolding system. N2-Lauroyl-L-glutamine can be synthesized enzymatically in glycerol-water system useing acylase I from pig kidney.<br>References Kudou, M. et al.: Protein Express. Purif., 75, 46 (2011); Wada, E. et al.: J. Am. Oil Chem. Soc., 79, 41 (2002);<br></p>

<p>Applications 4-Aminobutyl-d8 Guanidine is the labelled analog of the decarboxylation product of the amino acid arginine (A769500) and also an intermediate in polyamine biosynthesis.<br>References Golding, B.T., et al.: Biochem. Soc. Trans., 22, 391S (1994);<br></p>

<p>Applications Lacosamide is a medication used for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Lacosamide is a potent anticonvulsant.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Lees, G., et al.: Brain Res., 612, 190 (1993), Kuo, C., et al.: Mol. Pharmacol., 51, 1077 (1997), Barton, M., et al.: Epilepsy Res., 47, 217 (2001), Beyreuther, B., et al.: Eur. J. Pharmacol., 539, 64 (2006), Beyreuther, B., et al.: CNS Drug Rev., 13, 21 (2007),<br></p>

<p>Stability Hygroscopic<br>Applications (R)-2-Amino-N-benzyl-3-methoxypropionamide is an impurity of Lacosamide which is a potent anticonvulsant.<br>References Letiran, A., et al.: J. Med. Chem., 45, 4762 (2002); Wadavrao, S., et al.: Synthesis, 45, 3383 (2013)<br></p>

<p>Applications Isotope labelled L-Serine is used in the synthesis of purines and pyrimidines as antibacterial/antifungal agents, as well as acting as a proteinogenic compound.<br>References Olivella, M. et al.: Bioorg. Med. Chem., 20, 6109 (2012);<br></p>

<p>Stability Hygroscopic<br>Applications CEL and CML are two stable, nonenzymatic chemical modifications of protein lysine residues resulting from glycation and oxidation reactions.<br>References Fu, M.X., et al.: J. Biol. Chem., 271, 9982 (1996), Ahmed M.U., et al.: Biochem.J., 324, 565 (1997), Schleicher, E.D., et al.: J. Clin. Invest., 99, 457 (1997), Shibayama, R., et al.: Diabetes, 48, 1842 (1999),<br></p>